Biocompatibility and Haemocompatibility Assessments of RBC with Polymeric Coated Cardiac Stent.

Abstract

Listen

Translate article

The current investigation was conducted to evaluate the biocompatibility and hemocompatibility of polymeric-coated cardiac stents. Coronary stents are typically small wire mesh tubes that are used to open arteries that are obstructed over time as a result of the buildup of fat, cholesterol, or other materials. A 10 milliliter isolated blood red blood cell was obtained using the Prozeta cobalt chromium coronary stent, which had the following specifications: stent length = 18 mm, strut thickness = 0.065 mm, expansion range = 2.25 mm to 4.00 mm, and burst pressure = 6ATM. Using an R&D coating equipment, polyethylene glycol (PEG) polymers were applied to the coronary stent. Assessments of the polymeric-coated cardiac stent’s biocompatibility and hemocompatibility were conducted using various evaluation criteria. CAD software has been used to help with the stent’s modeling. According to the supplied catalog, the strut’s thickness and width are calculated to be 0.065 mm and its length is 18 mm. The histology of RBC in an isolated sample (polymer coated on stent) found at 2000 Rx was examined using a motic microscope. Using a UV-visible spectrophotometer set to 414 wave length, a 10µg/ml solution of RBC in distilled water was scanned at 200–500 nm to measure the UV absorption maximum. The absorbance was found to be 0.8312 nm. An FTIR analysis of RBC reveals absorptions that include bending and stretching vibrations. Peak Position was discovered at wave numbers 3661.76, 1684.62, 1547.98, 1472.07, 1278.06, and 841.98. Using SEM the surface morphology of RBC was study and it was found the measurements 6.1, 4.2, 3.3, 3.2, 3.1, and 2.2 µm in diameter with standard error 0.548584. It has been determined that PEG-coated material demonstrated significant outcomes that resulted in coronary stent that was both biocompatible and hemocompatible of polymeric-coated cardiac stent, which is a step towards altering the treatment regimen.